Genentech reported new results from two positive Phase III studies of fenebrutinib (FENhance 1 and FENhance 2) in relapsing multiple sclerosis, citing superiority versus teriflunomide on annualized relapse rate over 96 weeks. The company said ARR was reduced by 51.1% and 58.5%, respectively, with statistically significant p-values presented at the 2026 American Academy of Neurology Annual Meeting. Novartis also reported success in a pair of Phase III studies of remibrutinib (Rhapsido) in MS, describing “superiority” over Aubagio on relapse and inflammatory brain lesions, with clinically meaningful effects on disability progression. Novartis did not provide detailed outcomes in the brief, but emphasized liver safety, a key issue in BTK-inhibitor MS development. Together, the two reports sharpen the BTK-inhibitor race in MS, where multiple candidates have previously stumbled on efficacy or safety. Investors will now focus on full data, including lesion and disability endpoints, and whether liver-enzyme profiles support broader adoption.